Probiotics, prebiotics and symbiotics in inflammatory bowel diseases: state-of-the-art and new insights

Mario Cottone, Antonino Abbruzzo, Vincenzo Davide Palumbo, Giovanni Tomasello, Giuseppe Damiano, Angelo Leone, Francesco Damiani, Emanuele Sinagra, Attilio Ignazio Lo Monte, Francesco Cappello, Dario Raimondo, Maurizio Bellavia, Provvidenza Damiani, Zeenny, Emanuele Sinagra, Massimo Cocchi, Francesca Rossi, Tomasello, Facella, JurjusCappello, Gabriele Spinelli

Risultato della ricerca: Article

17 Citazioni (Scopus)

Abstract

Inflammatory bowel disease (IBD) consists of two distinct clinical forms, ulcerative colitis (UC) and Crohn s disease (CD), with unknown aetiology, which nevertheless are considered to share almost identical pathophysiological backgrounds. Up to date, a full coherent mechanistic explanation for IBD is still lacking, but people start to realize that the pathogenesis of IBD involves four fundamental components: the environment, gut microbiota, the immune system and the genome. As a consequence, IBD development might be due to an altered immune response and a disrupted mechanism of host tolerance to the non-pathogenic resident microbiota, leading to an elevated inflammatory response. Considering the available data arising from the scientific literature, here reviewed, in CD, a benefit of probiotics remains unproven; in UC, a benefit of probiotics remains unproven, even if E. coli Nissle 1917seems promising in maintaining remission and it could be considered an alternative in patients intolerant or resistant to 5-ASA preparations; in pouchitis, small controlled trials suggest a benefit from VSL no. 3 in the primary and secondary prevention of pouchitis; in IBD-associated conditions, a benefit of probiotics remains unproven. However, well-designed randomized control clinical trials are necessary to understand the undoubted role of these agents in the management of gut physiology in health and disease.
Lingua originaleEnglish
pagine (da-a)919-933
Numero di pagine15
RivistaJOURNAL OF BIOLOGICAL REGULATORS & HOMEOSTATIC AGENTS
Volume27
Stato di pubblicazionePublished - 2013

Fingerprint

Prebiotics
Probiotics
Inflammatory Bowel Diseases
Pouchitis
Ulcerative Colitis
Crohn Disease
Literature
Microbiota
Primary Prevention
Secondary Prevention
Immune System
Randomized Controlled Trials
Genome
Escherichia coli
Health

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Immunology and Allergy
  • Physiology
  • Immunology
  • Oncology
  • Endocrinology
  • Physiology (medical)
  • Cancer Research

Cita questo

Probiotics, prebiotics and symbiotics in inflammatory bowel diseases: state-of-the-art and new insights. / Cottone, Mario; Abbruzzo, Antonino; Palumbo, Vincenzo Davide; Tomasello, Giovanni; Damiano, Giuseppe; Leone, Angelo; Damiani, Francesco; Sinagra, Emanuele; Lo Monte, Attilio Ignazio; Cappello, Francesco; Raimondo, Dario; Bellavia, Maurizio; Damiani, Provvidenza; Zeenny; Sinagra, Emanuele; Cocchi, Massimo; Rossi, Francesca; Tomasello; Facella; Jurjus; Cappello; Spinelli, Gabriele.

In: JOURNAL OF BIOLOGICAL REGULATORS & HOMEOSTATIC AGENTS, Vol. 27, 2013, pag. 919-933.

Risultato della ricerca: Article

@article{34ff8f0c9cae4b0ab3a6dff83c19e6ce,
title = "Probiotics, prebiotics and symbiotics in inflammatory bowel diseases: state-of-the-art and new insights",
abstract = "Inflammatory bowel disease (IBD) consists of two distinct clinical forms, ulcerative colitis (UC) and Crohn s disease (CD), with unknown aetiology, which nevertheless are considered to share almost identical pathophysiological backgrounds. Up to date, a full coherent mechanistic explanation for IBD is still lacking, but people start to realize that the pathogenesis of IBD involves four fundamental components: the environment, gut microbiota, the immune system and the genome. As a consequence, IBD development might be due to an altered immune response and a disrupted mechanism of host tolerance to the non-pathogenic resident microbiota, leading to an elevated inflammatory response. Considering the available data arising from the scientific literature, here reviewed, in CD, a benefit of probiotics remains unproven; in UC, a benefit of probiotics remains unproven, even if E. coli Nissle 1917seems promising in maintaining remission and it could be considered an alternative in patients intolerant or resistant to 5-ASA preparations; in pouchitis, small controlled trials suggest a benefit from VSL no. 3 in the primary and secondary prevention of pouchitis; in IBD-associated conditions, a benefit of probiotics remains unproven. However, well-designed randomized control clinical trials are necessary to understand the undoubted role of these agents in the management of gut physiology in health and disease.",
author = "Mario Cottone and Antonino Abbruzzo and Palumbo, {Vincenzo Davide} and Giovanni Tomasello and Giuseppe Damiano and Angelo Leone and Francesco Damiani and Emanuele Sinagra and {Lo Monte}, {Attilio Ignazio} and Francesco Cappello and Dario Raimondo and Maurizio Bellavia and Provvidenza Damiani and Zeenny and Emanuele Sinagra and Massimo Cocchi and Francesca Rossi and Tomasello and Facella and Jurjus and Cappello and Gabriele Spinelli",
year = "2013",
language = "English",
volume = "27",
pages = "919--933",
journal = "JOURNAL OF BIOLOGICAL REGULATORS & HOMEOSTATIC AGENTS",
issn = "0393-974X",

}

TY - JOUR

T1 - Probiotics, prebiotics and symbiotics in inflammatory bowel diseases: state-of-the-art and new insights

AU - Cottone, Mario

AU - Abbruzzo, Antonino

AU - Palumbo, Vincenzo Davide

AU - Tomasello, Giovanni

AU - Damiano, Giuseppe

AU - Leone, Angelo

AU - Damiani, Francesco

AU - Sinagra, Emanuele

AU - Lo Monte, Attilio Ignazio

AU - Cappello, Francesco

AU - Raimondo, Dario

AU - Bellavia, Maurizio

AU - Damiani, Provvidenza

AU - Zeenny, null

AU - Sinagra, Emanuele

AU - Cocchi, Massimo

AU - Rossi, Francesca

AU - Tomasello, null

AU - Facella, null

AU - Jurjus, null

AU - Cappello, null

AU - Spinelli, Gabriele

PY - 2013

Y1 - 2013

N2 - Inflammatory bowel disease (IBD) consists of two distinct clinical forms, ulcerative colitis (UC) and Crohn s disease (CD), with unknown aetiology, which nevertheless are considered to share almost identical pathophysiological backgrounds. Up to date, a full coherent mechanistic explanation for IBD is still lacking, but people start to realize that the pathogenesis of IBD involves four fundamental components: the environment, gut microbiota, the immune system and the genome. As a consequence, IBD development might be due to an altered immune response and a disrupted mechanism of host tolerance to the non-pathogenic resident microbiota, leading to an elevated inflammatory response. Considering the available data arising from the scientific literature, here reviewed, in CD, a benefit of probiotics remains unproven; in UC, a benefit of probiotics remains unproven, even if E. coli Nissle 1917seems promising in maintaining remission and it could be considered an alternative in patients intolerant or resistant to 5-ASA preparations; in pouchitis, small controlled trials suggest a benefit from VSL no. 3 in the primary and secondary prevention of pouchitis; in IBD-associated conditions, a benefit of probiotics remains unproven. However, well-designed randomized control clinical trials are necessary to understand the undoubted role of these agents in the management of gut physiology in health and disease.

AB - Inflammatory bowel disease (IBD) consists of two distinct clinical forms, ulcerative colitis (UC) and Crohn s disease (CD), with unknown aetiology, which nevertheless are considered to share almost identical pathophysiological backgrounds. Up to date, a full coherent mechanistic explanation for IBD is still lacking, but people start to realize that the pathogenesis of IBD involves four fundamental components: the environment, gut microbiota, the immune system and the genome. As a consequence, IBD development might be due to an altered immune response and a disrupted mechanism of host tolerance to the non-pathogenic resident microbiota, leading to an elevated inflammatory response. Considering the available data arising from the scientific literature, here reviewed, in CD, a benefit of probiotics remains unproven; in UC, a benefit of probiotics remains unproven, even if E. coli Nissle 1917seems promising in maintaining remission and it could be considered an alternative in patients intolerant or resistant to 5-ASA preparations; in pouchitis, small controlled trials suggest a benefit from VSL no. 3 in the primary and secondary prevention of pouchitis; in IBD-associated conditions, a benefit of probiotics remains unproven. However, well-designed randomized control clinical trials are necessary to understand the undoubted role of these agents in the management of gut physiology in health and disease.

UR - http://hdl.handle.net/10447/88444

M3 - Article

VL - 27

SP - 919

EP - 933

JO - JOURNAL OF BIOLOGICAL REGULATORS & HOMEOSTATIC AGENTS

JF - JOURNAL OF BIOLOGICAL REGULATORS & HOMEOSTATIC AGENTS

SN - 0393-974X

ER -